The difference between information and
expert, data-driven actionable intelligence
Welcome to the November 2015 issue of CMC Market Outlook
This monthly e-newsletter provides valuable insights for both buyers and sellers of CMC drug development services. Our coverage will help you identify and understand market trends that will inform your strategic business perspective.
Enjoy the November issue!
CDMO Industry Update
PharmSource’s Jim Miller recently presented a CDMO industry update at our annual AAPS breakfast meeting. Strong financing is fueling pipeline growth and will continue to drive R&D, but how long will it last? Download these slides from Jim’s presentation to learn more.
How big is the market for…?
This is a handy guide to frequently requested data about the bio/pharma contract services industry.
The market for CMC development – total spending:
|2014: $22 billion||Catalent Pharma Solutions
Presentation at William Blair 35th Annual Growth Stock Conference
Read more about the size of the contract services market for various segments.
CMOs Ride Continuing Strength of Small-Molecule Drug Sector
by Jim Miller, President, PharmSource
It has been the general consensus among bio/pharmaceutical industry participants, investors, and observers that small-molecule drugs are becoming obsolete as the industry focuses on biologics. To paraphrase what Mark Twain allegedly said about his own situation, reports of the death of small-molecule drugs are greatly exaggerated.
Small-molecule pharmaceuticals accounted for 82% of all new drug application (NDA) approvals in 2014 and 60% of all new molecular entities. Further, they represent two-thirds of the drug-development pipeline. While there can be no doubt that the number and share of large-molecule therapeutics is increasing, small-molecule drugs are… read on
The Competitive Environment for Contract Dose Manufacturing
Our recently released 2015 Contract Dose Manufacturing Industry by the Numbers report is an indispensable resource for understanding the competitive environment faced by dose manufacturers, and provides critical insights for your strategic planning efforts. The report will enable you to:
- Benchmark your performance against other CMOs in the industry
- Understand what strategies CMOs are pursuing for profitable growth
- Grasp CMO business challenges affecting bio/pharmaceutical negotiations
Thanks to our deep expertise and ongoing research, Contract Dose Manufacturing Industry by the Numbers is the most authoritative and reliable portrait of the CMO industry available to the bio/pharmaceutical industry today.
Our proprietary model and assumptions are fully explained so you can understand how we arrived at our analysis and conclusions.
You won’t find this mission-critical information in any other source. Click here for more information or to order this report today.
PharmSource STRATEGIC ADVANTAGE
PharmSource’s STRATEGIC ADVANTAGE service is the industry’s most respected outsourcing information web portal for serious consumers of information on contract drug development and manufacturing. Developed from PharmSource’s expert proprietary research, you won’t find this information in any other resource.
See for yourself how this resource gives you vital tools for understanding the industry.
To request a test-drive today, contact Nathaniel Celentano at firstname.lastname@example.org / +1-703-383-4903, ext. 112 (ET USA).